Background: During the smoking of crack cocaine (COC), methyl ecgonidine (MED) is formed as one of the pyrolysis products. Once in the body, MED is converted to ecgonidine (ED) through several processes that include spontaneous hydrolysis and enzymatic hydrolysis. The presence of MED and/or ED could provide valuable information to help determine antemortem conditions in cases where COC is involved. Our goal was to examine postmortem tissues and fluids for the presence of MED, ED, COC, and benzoylecgonine (BZ). Methods: Liver, brain, blood, and urine specimens obtained from 15 postmortem cases were extracted using solid-phase extraction, derivatized, and analyzed using gas chromatography-mass spectrometry with selectiveion monitoring. 
Typically, biological tissues have been analyzed for cocaine (COC) 1 and/or COC metabolites to detect COC use, but defining the route of administration is difficult based on this information alone. Additional useful information may be obtained from the detection of methyl ecgonidine (MED), which has been reported as a pyrolysis product from COC smoking (1) (2) (3) . In actuality, the smoking of crack COC is greatly affected by individual technique, and the amount of COC inhaled is dependent on several factors (1, 4 -6 ) . The temperature in the pipe or smoking device has a significant impact on the amount of COC inhaled and on the amount of MED produced. At temperatures of 255-420°C, the amount of COC converted to MED is 50 -80% (4 ) and at a temperature of 650°C, as much as 89% of COC is converted to MED (1, 4 ) . These temperatures are not unrealistic because the glowing end of a cigarette can easily reach temperatures of ϳ800°C.
On the basis of this information, it would be reasonable
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to expect individuals smoking crack COC to inhale significant amounts of MED. As a result, the detection of MED would be a valuable marker to aid in identifying smoking as a route of administration and in estimating COC concentrations at the time of death. There are additional considerations in the analysis of MED. Once in the body, the concentration of MED might be expected to be lower because of conversion to ecgonidine (ED). The hydrolysis of MED to ED has been reported, and ED has been detected in human urine (7, 8 ) . Urine specimens that had tested positive for benzoylecgonine (BZ) in the military drug-testing program were tested for MED and ED. In 22 of the 23 specimens tested, ED was detected, and the concentrations were at least an order of magnitude greater than those of MED. These results suggest the value of quantifying both MED and ED to identify COC smoking as the route of administration.
Although MED and/or ED have been examined in various tissues and fluids (2, 3, (7) (8) (9) (10) (11) (12) (13) , MED has not been examined in liver and brain tissue, and ED has not been examined in liver, brain, and blood specimens. We examined the available specimens from 15 postmortem cases for the presence of MED, ED, COC, and BZ.
Materials and Methods chemicals, reagents, and supplies
, ecgonine, MED (anhydroecgonine methyl ester), and ED (anhydroecgonine) were purchased from Radian International. COC (free base) was purchased from Sigma Chemical, and dimethylformamide (DMF), DMF dipropyl acetal (DMF-DPA), and DMF dimethyl acetal were purchased form Aldrich Chemical. Solid-phase extraction (SPE) columns containing silica-based C 8 and SO 3 H (200 mg) and a glass extraction chamber were purchased from United Chemical Technologies. Reacti-vials, bis(trimethylsilyl)trifluoroacetamide (BSTFA), and N-methyl-N-(tert-butyldimethylsilyl)trifluoroacetamide (MTBSTFA) containing 1% tertbutyldimethylchlorosilane (TBDMCS) were purchased from Pierce. All solvents and reagents were analytical or HPLC grade. Acetone was dried over molecular sieves (3A, 8 -12 mesh) for at least 24 h.
specimens
Specimens from 15 postmortem cases were obtained from the Postmortem/Human Performance Laboratory, Division of Forensic Toxicology, Armed Forces Medical Examiners' Office, Armed Forces Institute of Pathology. The research protocol was approved by the Armed Forces Institute of Pathology Institutional Review Board. Specimens reported to be positive for COC/BZ had been screened positive by immunoassay, confirmed positive by gas chromatography-mass spectrometry (GC-MS), and stored frozen at Ϫ18°C for 6 months after testing was completed. Before use in this study, specimen identity was removed in preparation for disposal. Complete information concerning the specific source for each fluid and tissue was not available for any case. A significant impact on results was unlikely for the liver specimens because drug distribution in liver tissue would be expected to be uniform as a result of normal high hepatic profusion and metabolic activity. Brain tissue may have been obtained from various portions of the brain because there is no standardized procedure concerning the source of brain tissue. This most likely did not have a significant impact on our results, based on the reported uniform distribution of COC in postmortem brain tissue (14 ) . Urine was obtained directly from the bladder. In a few cases, blood specimens were obtained directly from the heart or from an intravenous catheter.
instrument
The Hewlett-Packard GC-MS system consisted of an HP 5890 Series II Plus gas chromatograph and a Model 5972 quadrupole mass-selective detector. An HP 18593B autoinjector was used to inject the samples into the GC-MS instrument.
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were added to the control tubes and to empty glass centrifuge tubes that were later used for specimen analysis.
Freshly prepared NaF (200 L; 10 g/L) was added to the tissues in the plastic tubes. The tissues were thawed, homogenized with 1 mL of 0.1 mol/L phosphate buffer (pH 6.0), and poured into the corresponding glass tubes containing drugs and internal standards for controls and internal standards only for specimens. Two milliliters of 0.1 mol/L phosphate buffer (pH 6.0) was then added to the residual tissue and homogenized again. The resulting homogenate was combined with the initial homogenate.
After homogenization, the tubes were capped and placed in an ice bath. The homogenates were vortexmixed for 10 -15 s and centrifuged for 60 min at 3834g at 7-10°C. A set of SPE columns was placed in the extraction chamber and conditioned with 3 mL each of methanol, water, and 0.1 mol/L phosphate buffer (pH 6.0), in that sequence, under slightly reduced pressure.
A set of glass centrifuge tubes was placed in the chamber to collect the next elution fraction (containing ED). The supernatants from the tissue homogenates were poured onto the columns and allowed to elute by gravity or under slightly reduced pressure. Deionized water (1 mL) was added to the columns, and that fraction was also collected. The tubes from the chamber were then removed and set aside for extraction of ED (Fig. 1) . The SPE columns were washed with 2 mL of deionized water, 3 mL of 0.1 mol/L HCl, and 3 mL of isopropanol, and then dried for 5 min under reduced pressure. The MED, COC, and BZ were then eluted with 3 mL of a mixture (9:1:0.2 by volume) of dichloromethane-methanol-aqueous NH 3 (14.8 mol/L).
The solutions were evaporated to dryness under nitrogen at room temperature to minimize loss of MED. The extracts were dissolved in 50 L of dry acetone, transferred into autosampler vials, and tested for MED and COC by two separate GC-MS procedures. After the MED and COC tests, the samples were tested for BZ as the propyl derivative, using another GC-MS procedure.
To extract ED from the eluates, the pH of the solutions was adjusted to 2.0 Ϯ 0.2 with 0.5 mol/L HCl. Methylene chloride (1 mL) was added to each tube and vortex-mixed. The solutions were centrifuged at 2177g for 3 min. The clear upper aqueous layers were then poured onto a second set of SPE columns preconditioned with 3 mL of methanol, 3 mL of deionized water, and 1 mL of 0.01 mol/L HCl. The solutions were allowed to elute by gravity flow or under slightly reduced pressure. The columns were washed with 1 mL of 0.1 mol/L HCl and 3 mL of methanol, and dried under reduced pressure for 5 min. The ED was eluted with 3 mL of a mixture (4:6:0.25 by volume) of methanol-isopropanol-aqueous NH 3 (14.8 mol/L). The solutions were evaporated under nitrogen at 50°C. To remove the white residue from ED, 2 mL of dry acetone was added. The solutions were vortex-mixed and centrifuged. The acetone solutions were separated and evaporated to dryness. The liver specimens were tested for ED as the tert-butyldimethylsilyl derivative by a GC-MS method, and the brain specimens were tested for ED as the trimethylsilyl derivative by GC-MS.
Urine and blood samples. An initial 3-mL aliquot of each urine specimen was prepared as published previously (7 ) . The procedure used for preparing blood specimens was the same as for the liver and brain tissues with the following exceptions. The initial 1-mL aliquots of blood were diluted with 4 mL of 0.1 mol/L phosphate buffer (pH 6.0). No methylene chloride wash was used in preparing the ED-containing fractions for the SPE steps.
derivatization
Propylation of BZ at the GC injection port for specimen analysis. After COC and MED analysis in acetone solution, DMF-DPA (20 L) was added to the autosampler vials. The contents were mixed, and the vials were recapped. Analysis was performed for propyl-BZ as reported previously (7 ).
Silylation of ED by MTBSTFA for specimen analysis. The extracts from liver and urine containing ED were dissolved in MTBSTFA containing 1% TBDMCS and prepared as described previously (7 ).
Silylation of ED by BSTFA for specimen analysis. The extracts from brain and blood containing ED were dissolved in 50 L of BSTFA and heated in closed tubes at 70°C for 15 min. The samples were centrifuged immediately at 7-10°C for 2-3 min at 1700g and transferred to autosampler vials for GC-MS analysis. 
gc-ms analysis
Samples were introduced in 1-to 4-L volumes using an autoinjector. The GC analysis was performed using a DB-5MS capillary column 
GC-MS conditions for
Because COC, BZ, and MED were extracted together, injector temperatures were kept Յ140°C to avoid possible formation of MED from any COC present in the sample. After each injection, 2-3 L of acetone was injected as a solvent blank.
GC-MS conditions for COC.
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GC-MS conditions for propyl BZ.
The analysis was performed at injector and transfer line temperatures of 280 and 270°C, respectively. The oven temperature started at 170°C (held for 0.5 min) and increased to 270°C at 30°C/min (held for 2.7 min). The GC was started in splitless mode, and injector port purge was turned on after 0. 
GC-MS conditions for tert-butyldimethylsilyl ED.
The analysis was performed at injector and transfer line temperatures of 250 and 270°C, respectively. The oven temperature started at 135°C (held for 0.5 min), increased to 175°C at 10°C/min (held for 0.5 min), and increased to 275°C at 30°C/min (held for 1 min). The GC was started in splitless mode, and injector port purge was turned on after 0. 
statistical analysis
The statistical analysis of the data sets was performed using ANOVA. To be a significant difference, both sets had to show a difference at P Ͻ0.05.
Results and Discussion
MED is a pyrolytic product of COC. Both MED and ED are also produced as artifacts from COC or COC metabolites during GC-MS analysis (7 ) . Therefore, suitable analytical conditions are necessary to test MED and ED in body fluids and tissues. In the extraction, ED was separated from other drugs by selective adsorption on the SPE columns (C 8 and SO 3 H). At pH 6.0 Ϯ 0.5, most of the COC, BZ, and MED (Ͼ90%) were retained on the column, whereas ED, which did not adsorb, passed through the column and was collected. ED was then extracted from the solution by adjusting the pH to 2-3 and allowing it to pass through a second column. At this pH, ED was more lipophilic and suitable for column adsorption. The compound was then eluted with a mixture of polar solvents [methanol-isopropanol-ammonia (4:6:0.25 by volume)].
To elute MED, COC, and BZ from the first column, dichloromethane-methanol-ammonia (9:1:0.2 by volume) was preferred over the generally used dichlorobutaneisopropanol-ammonia (8:2:0.2 by volume) because MED 1  0  13  0  30  0  126  37  917  2  0  36  0  60  0  468  155  2084  3  N A   b is volatile and easily lost during evaporation of the higher boiling isopropanol. Separation of ED from COC and COC metabolites minimized the formation of artifact ED. MED in the extract of COC and BZ was analyzed separately at a GC injection port temperature of Յ140°C. Higher tempera- tures were avoided to minimize formation of artifact MED. To ensure that artifacts were not formed during analysis, a control containing COC, BZ, EC, and MEC at 1, 5, 5, and 5 mg/L, respectively, was tested. No ED or MED was detected under the extraction and GC-MS conditions described. COC was also injected separately before derivatization of BZ because the alkylating agents contained a small amount of methylating agent as impurity. In our experiment, DMF-DPA, DMF-diisopropylamide, or DMFdiethylamide with only BZ produced a small amount of COC as byproduct (Ͻ1%). Although MED and COC were injected under two different conditions (injection temperatures 140 and 280°C, respectively), the samples could be analyzed in one injection batch by use of an autoinjector with two GC-MS settings. ED extracted from blood and brain and tested as the tert-butyldimethylsilyl derivative showed chromatographic background. Analyzing the compound as the trimethylsilyl derivative minimized the background. The linearity, correlation coefficient squared (r 2 ), limit of quantification (LOQ), and extraction efficiency are summarized in Table 1 . In the range of linearity, all compounds showed ion ratios within Ϯ 20% of the mean values. At least eight concentrations were used in the range of linearity. Only one sample was tested at each concentration. Good correlation (r 2 ) was observed in the linear range mentioned, where acceptable values were defined as Ն0.9900. Signal-to-noise ratios in all analyses were Ͼ4:1. In this study, LOQ was defined as the concentration at which one of the two ion ratios was outside Ϯ 20% but within Ϯ 30% and the concentration was within Ϯ 20% of expected value. Quantification ions in some compounds showed better chromatographic background, allowing a LOQ below the limit of linearity. This observation was most likely attributable to the variability of the biological matrices among the various tissues and fluids. Specimens were analyzed in several batches, and controls at concentrations of 0, 20, 50, and 100 g/L were used in each batch analysis to validate the results. The criteria for batch validation were the same as those used for linearity studies.
Case histories for the specimens were extremely limited, although preliminary causes of death were not attributed to drug overdose. The results from the analyses by drug are summarized in Tables 2 and 3 . Fig. 2 shows chromatograms for ED extracted from blood specimen 4 ( Fig. 2a) and MED extracted from brain specimen 11 (Fig.  2b) , where the concentrations were 25 g/L and 22 ng/g, respectively. The ranges for MED concentrations in liver, brain, blood, and urine were 0 -10 ng/g, 0 -92 ng/g, 0 -42 g/L, and 0 -2030 g/L, respectively. The number of samples in which MED was detected was 5 of 15, 7 of 14, 3 of 11, and 10 of 13 in liver, brain, blood, and urine, respectively. Although MED was detected in 5 of 15 liver specimens, the observed concentrations did not exceed 10 ng/g in any specimen. In contrast, urine concentrations as high as 2030 g/L were observed, and 6 of the 13 urine specimens reached concentrations in excess of 100 g/L. In general, MED concentrations were much lower in brain than in urine. The range of MED concentrations in the liver specimens was slightly larger than in the brain specimens. Although examining brain for estimating COC concentrations at the time of death may have some advantage because of the free passage of COC across the blood-brain barrier, the characteristics of MED relative to the blood-brain barrier have not been established. The high number of blood samples negative for MED or with low MED concentrations may indicate that detection of MED may be difficult in blood and be of limited usefulness in the estimation of COC concentrations at the time of death. On the basis of these observations along with other concerns for the use of blood in evaluating COC use in postmortem cases (15 ) , other tissues and/or fluids may be more useful in postmortem examinations.
ED concentrations were noticeably higher than MED in liver, blood, and urine. In liver, the median ED concentration was 655 ng/g (range, 90 -3274 ng/g) compared with 0 ng/g (range, 0 -10 ng/g) for MED. Similar results were observed in blood. The amount of ED was relatively low in brain, and there was no statistical difference compared with MED concentrations in brain tissue. This indicates that ED does not easily pass through the bloodbrain barrier, which might be expected based on the hydrophilic nature of ED, and may also be accompanied by extensive first-or second-pass metabolism of MED in the liver and efficient excretion of ED by the body via the kidneys. This may also indicate that any MED that may enter the brain is converted to ED via enzymatic hydrolysis at a very low rate, which may parallel the observation that cocaine methyl esterase activity in brain is only 1-6% compared with liver in rats (16 ) . Although MED was detected in only 3 of 11 blood specimens, ED was detected in all blood specimens. This suggests that MED is extensively converted to ED in the blood as well as in the liver, which is supported by the previously reported hydrolysis of MED to ED in liver homogenates (7 ) and the enzymatic hydrolysis observed in unpreserved sheep plasma (17 ) .
When the ED concentrations in liver and urine were compared, 6 of 13 specimens contained more ED in liver than in urine. In 8 of 15 liver specimens, the amount of ED actually exceeded the amount of BZ. ED was detected in all 15 cases (50 of 53 total specimens), indicating that smoking was a route of COC administration. Compared with the detection of MED in 12 of 15 cases (25 of 53 total specimens), ED appears to be more easily detected than MED and may be a more useful marker than MED for determination of COC smoking in postmortem cases.
In conclusion, a review of the data reveals that ED concentrations were significantly higher than MED concentrations in liver, blood, and urine. In brain the difference was not significant. Of 53 tissue and fluid specimens collected from 15 postmortem cases, 50 specimens were positive for ED compared with only 25 specimens positive for MED. Only three brain specimens were negative for ED. The presence of ED and MED suggests that smoking was the route of COC administration in all 15 postmortem cases.
